Evidence map›Paper›PMID 34500854›Full record

ArticleMolecules (Basel, Switzerland)2021

Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.

Ðenana Miodragović, Wenan Qiang, Zohra Sattar Waxali, Željko Vitnik, Vesna Vitnik, Yi Yang, Annie Farrell, Matthew Martin, Justin Ren, Thomas V O'Halloran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Ðenana MiodragovićDepartment of Chemistry, Northeastern Illinois University, 5500 St. Louis Ave, Chicago, IL 60625, USA.ORCID 0000-0001-8252-3320
Wenan QiangChemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA.ORCID 0000-0001-5068-7128
Zohra Sattar WaxaliChemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA.
Željko VitnikInstitute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.ORCID 0000-0003-0276-9238
Vesna VitnikInstitute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.ORCID 0000-0003-3821-7240
Yi YangChemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA.
Annie FarrellDepartment of Chemistry, University of Illinois at Urbana Champaign, 102 N. Neil St., Champaign, IL 61820, USA.
Matthew MartinDepartment of Chemistry, Northeastern Illinois University, 5500 St. Louis Ave, Chicago, IL 60625, USA.
Justin RenChemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA.
Thomas V O'HalloranChemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA.
Northwestern University · USUniversity of Belgrade · RSNortheastern Illinois University · USUniversity of Illinois Urbana-Champaign · US

Funding

Spatio-Temporal Organization of Chromatin and Information Transfer in CancerU54CA193419 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN D., O'HALLORAN, THOMAS V · 2015 to 2020
$10.4M
Developing Capacity to Evaluate Training Programs via Development of Human, Institutional and Social CapitalT32GM008449 · NIGMS · NORTHWESTERN UNIVERSITY · PI LEONARD, JOSHUA NATHANIEL · 1993 to 2023
$7.8M
Ministry of Education, Science, and Technological Development of the Republic of Serbia 453-03-9/2021-14/200026NCI NIH HHS U54 CA193419NIGMS NIH HHS T32 GM008449NIH HHS U54CA202995, U54CA202997, U54CA203000, U54CA1934419, T32GM008449
6 · The paper itself

Abstract

Patients with triple negative breast cancers (TNBCs)-highly aggressive tumors that do not express estrogen, progesterone, and human epidermal growth factor 2 receptors-have limited treatment options. Fewer than 30% of women with metastatic TNBC survive five years after their diagnosis, with a mortality rate within three months after a recurrence of 75%. Although TNBCs show a higher response to platinum therapy compared to other breast cancers, drug resistance remains a major obstacle; thus, platinum drugs with novel mechanisms are urgently needed. Arsenoplatins (APs) represent a novel class of anticancer agents designed to contain the pharmacophores of the two FDA approved drugs cisplatin and arsenic trioxide (As

Indexed as

Antineoplastic AgentsApoptosisArsenic TrioxideCell Line, TumorCell ProliferationCisplatinDrug ResistanceDrug Therapy, CombinationHumansIodidesMolecular ConformationPharmaceutical PreparationsSpatial AnalysisStructure-Activity RelationshipTriple Negative Breast NeoplasmsAntineoplastic AgentsArsenic TrioxideCisplatinIodidesPharmaceutical Preparationsantiproliferative activityarsenic trioxidearsenoplatincisplatinDFTtriple negative breast cancersX-ray structure

Identifiers

PMID34500854
PMCPMC8434261
OpenAlexW3197062093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.